<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1208210932
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Megmento
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MICAFUNGIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        357
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Farmaceutica" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Farmaceutica
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J02AX05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Megmento contains the active substance micafungin. Megmento is called an antifungal medicine because it is used to treat infections caused by fungal cells.</p><p>Megmento is used to treat fungal infections caused by fungal or yeast cells called Candida. Megmento is effective in treating systemic infections (those that have penetrated within the body). It interferes with the production of a part of the fungal cell wall. An intact cell wall is necessary for the fungus to continue living and growing. Megmento causes defects in the fungal cell wall, making the fungus unable to live and grow.</p><p>Your doctor has prescribed Megmento for you in the following circumstances when there are no other suitable antifungal treatments available (see section 2):</p><ul><li>To treat adults, adolescents and children including neonates who have a serious fungal infection called invasive candidiasis (infection that has penetrated the body).</li><li>To treat adults and adolescents &ge; 16 years of age who have a fungal infection in the gullet (oesophagus) where treatment into a vein (intravenous) is appropriate.</li><li>To prevent infection with Candida in patients who are having a bone-marrow transplant or who are expected to have a neutropenia (low levels of neutrophils, a type of white blood cell) for 10 days or more.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Megmento </strong></p><ul><li>If you are allergic to micafungin, other echinocandins (anidulafungin or caspofungin) or any of the other ingredients of this medicine (listed in section 6).</li></ul><p><strong>Warnings and Precautions </strong></p><p>In rats, long-term treatment with micafungin led to liver damage and subsequent liver tumours. The potential risk of developing liver tumours in humans is not known, and your doctor will assess the benefits and risks of micafungin treatment before starting your medicine. Please tell your doctor if you have severe liver problems (e.g. liver failure or hepatitis) or have had abnormal liver function tests. During treatment your liver functions will be monitored more closely.</p><p>Talk to your doctor or pharmacist before using Megmento</p><ul><li>If you are allergic to any medicine</li><li>If you have haemolytic anaemia (anaemia due to breakdown of red blood cells) or haemolysis (breakdown of red blood cells).</li><li>If you have kidney problems (e.g. kidney failure and abnormal kidney function test). If this happens, your doctor may decide to monitor your kidney function more closely.</li></ul><p>Micafungin may also cause severe inflammation/eruption of the skin and mucous membranes (Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p><strong>Other medicines and Megmento</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>It is especially important to inform your doctor if you are using amphotericin B desoxycholate or itraconazole (antifungal antibiotics), sirolimus (an immunosuppressant) or nifedipine (calcium channel blocker used to treat high blood pressure). Your doctor may decide to adjust the dose of these medicines.</p><p><strong>Megmento with food and drink</strong></p><p>As Megmento is given intravenously (into a vein), no restrictions on food or drink are required.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant of breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>Megmento should not be used during pregnancy unless clearly necessary. If you use Megmento you should not breast-feed.</p><p><strong>Driving and using machines </strong></p><p>&nbsp;Micafungin is unlikely to have an effect on driving or using machines. However some people may feel dizzy when taking this medicine and if this happens to you, do not drive or use any tools or machines. Please inform your doctor if you experience any effects that may cause you to have problems with driving or using other machinery.</p><p><strong>Megmento</strong><strong> </strong><strong>contains sodium.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Megmento must be prepared and given to you by a doctor or another healthcare professional.</p><p>Megmento should be administered once daily by slow intravenous (into a vein) infusion. Your doctor will determine how much Megmento you will receive each day.</p><p><strong>Use in adults, adolescents &ge; 16 years of age and elderly</strong></p><ul><li>The usual dose to treat an invasive Candida infection is 100 mg per day for patients weighing 40 kg or more and 2 mg/kg per day for patients weighing 40 kg or less.</li><li>The dose to treat a Candida infection of the oesophagus is 150 mg for patients weighing more than 40 kg and 3 mg/kg per day for patients weighing 40 kg or less.</li><li>The usual dose to prevent invasive Candida infections is 50 mg per day for patients weighing more than 40 kg and 1 mg/kg per day for patients weighing 40 kg or less.</li></ul><p><strong>Use in children &gt; 4 months of age and adolescents &lt; 16 years of age </strong></p><ul><li>The usual dose to treat an invasive Candida infection is 100 mg per day for patients weighing 40 kg or more and 2 mg/kg per day for patients weighing 40 kg or less.</li><li>The usual dose to prevent invasive Candida infections is 50 mg per day for patients weighing more than 40 kg and 1 mg/kg per day for patients weighing 40 kg or less.</li></ul><p><strong>Use in children and newborns &lt; 4 months of age</strong></p><ul><li>The usual dose to treat an invasive Candida infection is 4-10 mg/kg per day.</li><li>The usual dose to prevent invasive Candida infections is 2 mg/kg per day.</li></ul><p><strong>If you receive more Megmento than you should</strong></p><p>Your doctor monitors your response and condition to determine what dose of Megmento is needed. However, if you are concerned that you may have been given too much Megmento, speak to your doctor or another healthcare professional immediately.</p><p><strong>If you miss a dose of Megmento</strong></p><p>Your doctor monitors your response and condition to determine what Megmento treatment is needed. However, if you are concerned that you may have missed a dose, speak to your doctor or another healthcare professional immediately.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you experience an allergic attack, or a severe skin reaction (e.g. blistering and peeling of the skin), you must inform your doctor or nurse immediately.</p><p><strong><em>Micafungin may cause the following other side effects:</em></strong></p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><ul><li>Abnormal blood tests (decreased white blood cells [leucopenia; neutropenia]); decreased red blood cells (anaemia)</li><li>Decreased potassium in the blood (hypokalaemia); decreased magnesium in the blood (hypomagnesaemia); decreased calcium in the blood (hypocalcaemia)</li><li>Headache</li><li>Inflammation of the vein wall (at injection-site)</li><li>Nausea (feeling sick); vomiting (being sick); diarrhoea; abdominal pain</li><li>Abnormal liver function tests (increased alkaline phosphatase; increased aspartate aminotransferase, increased alanine aminotransferase)</li><li>Increased bile pigment in the blood (hyperbilirubinaemia)</li><li>Rash</li><li>Fever</li><li>Rigors (shivering)</li></ul><p><strong>Uncommon</strong> (may affect up to 1 in 100 people)</p><ul><li>Abnormal blood tests (decreased blood cells [pancytopenia]); decreased blood platelets (thrombocytopenia); increases in a certain type of white blood cells called eosinophils; decreased albumin in the blood (hypoalbuminaemia)</li><li>Hypersensitivity</li><li>Increased sweating</li><li>Decreased sodium in the blood (hyponatraemia); increased potassium in the blood (hyperkalaemia); decreased phosphates in the blood (hypophosphataemia); anorexia (eating disorder)</li><li>Insomnia (difficulty in sleeping); anxiety; confusion</li><li>Feeling lethargic (somnolence); trembling; dizziness; disturbed taste</li><li>Increased heart rate; stronger heartbeat; irregular heartbeat</li><li>High or low blood pressure; skin flushing</li><li>Shortness of breath</li><li>Indigestion; constipation</li><li>Liver failure; increased liver enzymes (gamma-glutamyltransferase); jaundice (yellowing of the skin or whites of the eyes caused by liver or blood problems); reduced bile reaching the intestine (cholestasis); enlarged liver; liver inflammation</li><li>Itchy rash (urticaria); itching; skin flushing (erythema)</li><li>Abnormal kidney function tests (increased blood creatinine; increased urea in the blood); aggravated kidney failure</li><li>Increase in an enzyme called lactate dehydrogenase</li><li>Clotting in vein at injection-site; inflammation at injection-site; pain at injection-site; collection of fluid in your body</li></ul><p><strong>Rare</strong> (may affect up to 1 in 1,000 people)</p><ul><li>Anaemia due to breakdown of red blood cells (haemolytic anaemia), breakdown of red blood cells (haemolysis)</li></ul><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><ul><li>Disorder of blood clotting system</li><li>(allergic) shock</li><li>Damage to liver cells including death</li><li>Kidney problems; acute kidney failure</li></ul><p><strong><em>Additional side effects in children and adolescents</em></strong></p><p>The following reactions have been reported more often in paediatric patients than in adult patients:</p><p><strong>Common</strong> (may affect up to 1 in 10 people)</p><ul><li>Decreased blood platelets (thrombocytopenia)</li><li>Increased heart rate (tachycardia)</li><li>High or low blood pressure</li><li>Increased bile pigment in the blood (hyperbilirubinaemia); enlarged liver</li><li>Acute kidney failure; increased urea in the blood</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Unopened vial: Do not store above 30&deg;C.</p><p>Store in the original package.</p><p>The reconstituted concentrate and the diluted infusion solution should be used immediately, because it does not contain any preservatives to prevent bacterial contamination. Only a trained healthcare professional who has read the complete directions properly can prepare this medicine for use.</p><p>In order to protect the infusion bottle/bag containing the diluted infusion solution from light it should be inserted into a closable opaque bag.</p><p>The vial is for single use only. Therefore, please discard unused reconstituted concentrate immediately.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not use the diluted infusion solution if it is cloudy or precipitated.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is micafungin sodium.</p><p>Each vial of Megmento 50 mg Powder for Solution for Infusion contains 50.86 mg micafungin sodium equivalent to 50 mg micafungin.</p><p>Each vial of Megmento 100 mg Powder for Solution for Infusion contains 101.73 mg micafungin sodium equivalent to 100 mg micafungin.</p><p>The other ingredients are lactose monohydrate, citric acid anhydrous and sodium hydroxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Megmento 50 mg Powder for Solution for Infusion is white cake free from visible signs of contamination in 10 ml type I tubular amber glass vials with 20 mm neck, 20 mm bromobutyl Lyo stopper and 20 mm blue aluminum flip-off cap.
Megmento 100 mg Powder for Solution for Infusion is white cake free from visible signs of contamination in 10 ml type I tubular amber glass vials with 20 mm neck, 20 mm bromobutyl Lyo stopper and 20 mm red aluminum flip-off cap.
Pack size: 1 Vial.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder</strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. BOX 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 4980170&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br />Fax: + (966-11) 4980187<br />e-mail: <u>medical@jpi.com.sa</u></p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica&nbsp; S.A.</p><p>Estrada do Rio Da M&oacute;, n.&deg;8, 8A e 8B</p><p>Ferven&ccedil;a</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 05/2019; version number SA1.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ميجمنتو على المادة الفعالة ميكافونجين. يسمى ميجمنتو بالدواء المضاد للفطريات لأنه يستخدم لعلاج العدوى التي تسببها الخلايا الفطرية.</p><p dir="RTL">يستخدم ميجمنتو لعلاج العدوى الفطرية التي تسببها الخلايا الفطرية أو خلايا الخميرة التي تسمى الفطريات المبيضة. ميجمنتو فعال في علاج العدوى الجهازية (تلك التي تخترق داخل الجسم). يتداخل مع تصنيع جزء من جدار الخلية الفطرية. جدار الخلية السليم ضروري للفطريات لمواصلة العيش والنمو. ميجمنتو يسبب عيوب في جدار الخلية الفطرية، مما يجعل الفطريات غير قادرة على العيش والنمو.</p><p dir="RTL">يصف طبيبك ميجمنتو لك في الحالات التالية عندما لا تتوفر علاجات مضادة للفطريات مناسبة أخرى (انظر القسم 2):</p><ul dir="rtl"><li>لعلاج البالغين، المراهقين والأطفال بما في ذلك الأطفال حديثي الولادة الذين لديهم عدوى فطرية خطيرة تسمى داء المبيضات الفطرية الغزوية (العدوى التي اخترقت الجسم).</li><li>لعلاج البالغين والمراهقين الذين أعمارهم &ge; 16 سنة والذين يعانون من عدوى فطرية في المريء حيث يكون العلاج في الوريد (عن طريق الوريد) مناسباً.</li><li>لمنع الإصابة بعدوى المبيضات الفطرية في المرضى الذين يخضعون لزرع نخاع العظم أو الذين يتوقع أن يكون لديهم قلة العدلات (انخفاض مستويات العدلات، نوع من خلايا الدم البيضاء) لمدة 10 أيام أو أكثر.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم ميجمنتو</strong></p><p dir="RTL">إذا كنت تعاني من حساسية تجاه الميكافونجين، أو زمرة ايكينوكاندين الأخرى (أنيدولافنجين أو كاسبوفنجين) أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL"><strong>الاحتياطات والتحذيرات</strong></p><p dir="RTL">في الفئران، أدى العلاج على المدى الطويل مع الميكافونجين إلى تلف الكبد وأورام الكبد اللاحقة. لا يُعرف الخطر المحتمل للإصابة بأورام الكبد لدى الإنسان، وسيقوم طبيبك بتقييم فوائد ومخاطر علاج الميكافونجين قبل البدء في تناول الدواء. يرجى إخبار طبيبك إذا كنت تعاني من مشاكل شديدة في الكبد (مثل قصور الكبد أو التهاب الكبد) أو سبق وكان لديك اختبارات غير طبيعية في وظائف الكبد. أثناء العلاج، سيتم مراقبة وظائف الكبد عن قرب.</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل استخدام &nbsp;ميجمنتو</p><ul dir="rtl"><li>إذا كنت تعاني من حساسية تجاه أي دواء</li><li>إذا كان لديك فقر الدم الانحلالي (فقر الدم الناجم عن تكسر خلايا الدم الحمراء) أو انحلال الدم (تكسر خلايا الدم الحمراء).</li><li>إذا كنت تعاني من مشاكل في الكلى (مثل القصور الكلوي واختبارات وظائف الكلى غير طبيعية). إذا حدث هذا، فقد يقرر طبيبك مراقبة وظائف الكلى عن قرب.</li></ul><p dir="RTL">قد يسبب الميكافونجين أيضاً التهاب شديد/تنفط في الجلد والأغشية المخاطية (متلازمة ستيفنز جونسون، تنخر البشرة السمي).</p><p dir="RTL"><strong>الأدوية الأخرى وميجمنتو</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">من المهم بشكل خاص إبلاغ طبيبك إذا كنت تستخدم الأمفوتريسين ب ديوكسيكولات أو إيتراكونازول (المضادات الحيوية المضادة للفطريات)، سيروليمس (أحد مثبطات المناعة) أو نيفيديبين (حاصرات قنوات الكالسيوم المستخدم لعلاج ارتفاع ضغط الدم). قد يقرر طبيبك ضبط جرعة هذه الأدوية.</p><p dir="RTL"><strong>ميجمنتو مع الطعام والشراب</strong></p><p dir="RTL">نظراً لأن ميجمنتو يتم إعطاؤه عن طريق الوريد (في الوريد)، لا يلزم فرض قيود على الطعام أو الشراب.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنت حاملاً أو تقومين بالرضاعة الطبيعية، تعتقدين بأنك قد تكونين حاملاً أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p dir="RTL">لا ينبغي استخدام ميجمنتو أثناء الحمل ما لم يكن ذلك ضرورياً بشكل واضح. إذا كنت تستخدمين ميجمنتو، فلا ينبغي عليك القيام بالرضاعة الطبيعية.</p><p dir="RTL"><strong>تأثير ميجمنتو على القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المرجح أن يكون لميكافونجين تأثير على القيادة أو استخدام الآلات. ومع ذلك، قد يشعر بعض الأشخاص بالدوخة عند تناول هذا الدواء، وإذا حدث لك ذلك، فلا تقود السيارة أو تستخدم أي أدوات أو آلات. يرجى إبلاغ طبيبك إذا واجهت أي آثار قد تسبب لك مشاكل في القيادة أو استخدام الآلات الأخرى.</p><p dir="RTL"><strong>يحتوي ميجمنتو على الصوديوم.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب تحضير ميجمنتو وإعطائه لك من قبل طبيب أو أخصائي رعاية صحية آخر.</p><p dir="RTL">يجب إعطاء ميجمنتو مرة واحدة يومياً عن طريق الحقن الوريدي البطيء (في الوريد). سيحدد طبيبك مقدار ميجمنتو الذي ستتلقاه كل يوم.</p><p dir="RTL"><strong>الاستخدام لدى الأطفال، المراهقين&ge; 16 سنة والكبار</strong></p><ul dir="rtl"><li>الجرعة المعتادة لعلاج عدوى المبيضات الفطرية الغزوية هي 100 ملغم يومياً للمرضى الذين يبلغ وزنهم 40 كغم أو أكثر و2 ملغم/كغم يومياً للمرضى الذين يبلغ وزنهم 40 كغم أو أقل.</li><li>الجرعة لعلاج عدوى المبيضات الفطرية في المريء هي 150 ملغم للمرضى الذين يزيد وزنهم عن 40 كغم و3 ملغم/كغم يومياً للمرضى الذين يبلغ وزنهم 40 كغم أو أقل.</li><li>الجرعة المعتادة لمنع عدوى المبيضات الفطرية الغزوية هي 50 ملغم يومياً للمرضى الذين يزيد وزنهم عن 40 كغم و1 ملغم/كغم يومياً للمرضى الذين يبلغ وزنهم 40 كغم أو أقل.</li></ul><p dir="RTL"><strong>&nbsp;الاستخدام لدى الأطفال الذين تزيد أعمارهم عن 4 شهور والمراهقين الذين تقل أعمارهم عن 16 عاماً</strong></p><ul dir="rtl"><li>الجرعة المعتادة لعلاج عدوى المبيضات الفطرية الغزوية هي 100 ملغم يومياً للمرضى الذين يبلغ وزنهم 40 كغم أو أكثر و2 ملغم/كغم يومياً للمرضى الذين يبلغ وزنهم 40 كغم أو أقل.</li><li>الجرعة المعتادة لمنع عدوى المبيضات الفطرية الغزوية هي 50 ملغم يومياً للمرضى الذين يزيد وزنهم عن 40 كغم و1 ملغم/كغم يومياً للمرضى الذين يبلغ وزنهم 40 كغم أو أقل.</li></ul><p dir="RTL"><strong>الاستخدام لدى الأطفال وحديثي الولادة أقل من 4 أشهر من العمر</strong></p><ul dir="rtl"><li>الجرعة المعتادة لعلاج عدوى المبيضات الفطرية الغزوية هي 4-10 ملغم/كغم في اليوم.</li><li>الجرعة المعتادة لمنع عدوى المبيضات الفطرية الغزوية هي 2 ملغم/كغم في اليوم.</li></ul><p dir="RTL"><strong>إذا تناولت جرعة زائدة من ميجمنتو</strong></p><p dir="RTL">يقوم طبيبك بمراقبة استجابتك وحالتك لتحديد جرعة ميجمنتو المطلوبة. ومع ذلك، إذا كنت تشعر بالقلق من أنه قد تم إعطاؤك الكثير من ميجمنتو، فتحدث إلى طبيبك أو مقدم رعاية صحية آخر على الفور.</p><p dir="RTL"><strong>إذا نسيت تناول ميجمنتو</strong></p><p dir="RTL">يراقب طبيبك استجابتك وحالتك لتحديد علاج ميجمنتو المطلوب. ومع ذلك، إذا كنت تشعر بالقلق من أنك قد فاتتك جرعة، فعليك التحدث مع طبيبك أو مقدم رعاية صحية آخر على الفور.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL">إذا كنت تعاني من نوبة تحسسية، أو رد فعل جلدي شديد (مثل تقرحات الجلد وتقشيره)، يجب عليك إخبار طبيبك أو ممرضتك على الفور.</p><p dir="RTL"><strong><em>قد يسبب </em></strong><strong><em>ميكافونجين</em></strong><strong><em> الآثار الجانبية الأخرى التالية</em></strong><strong><em>:</em></strong></p><p dir="RTL"><strong>شائعة</strong> (قد تؤثر على ما يصل إلى 1 شخص من 10 أشخاص)</p><ul dir="rtl"><li>اختبارات الدم غير الطبيعية (نقص خلايا الدم البيضاء [قلة خلايا الدم البيضاء، قلة العدلات])؛ انخفاض خلايا الدم الحمراء (فقر الدم)</li><li>انخفاض البوتاسيوم في الدم (نقص بوتاسيوم الدم)؛ نقص المغنيسيوم في الدم (نقص مغنيسيوم الدم)؛ نقص الكالسيوم في الدم (نقص كالسيوم الدم)</li><li>صداع</li><li>التهاب جدار الوريد (في موضع الحقن)</li><li>الغثيان؛ القيء؛ إسهال؛ وجع في البطن</li><li>اختبارات وظائف الكبد غير الطبيعية (زيادة أنزيم الفوسفاتيز القلوي؛ زيادة ناقل أمين الأسبارتات، زيادة ناقل أمين الألانين)</li><li>زيادة صبغة صفراء المرارة في الدم (فرط بيليروبين الدم)</li><li>طفح جلدي</li><li>حمّى</li><li>ارتعاش</li></ul><p dir="RTL"><strong>غير شائعة</strong> (قد تؤثر على ما يصل إلى شخص من 100 شخص)</p><ul dir="rtl"><li>اختبارات الدم غير الطبيعية (انخفاض خلايا الدم [قلة الكريات الشاملة])؛ انخفاض الصفائح الدموية في الدم (نقص الصفيحات)؛ زيادة في نوع معين من خلايا الدم البيضاء تسمى اليوزنات؛ انخفاض الألبيومين في الدم (نقص ألبيومين الدم)</li><li>فرط الحساسية</li><li>زيادة التعرق</li><li>انخفاض الصوديوم في الدم (نقص صوديوم الدم)؛ زيادة البوتاسيوم في الدم (فرط بوتاسيوم الدم)؛ انخفاض الفوسفات في الدم (نقص فوسفات الدم)؛ فقدان الشهية (اضطراب الأكل)</li><li>الأرق (صعوبة في النوم)؛ القلق؛ الارتباك</li><li>الشعور بالخمول (نعاس)؛ ارتجاف؛ دوخة؛ اضطراب في التذوق</li><li>زيادة معدل ضربات القلب؛ ضربات قوية؛ عدم انتظام ضربات القلب</li><li>ارتفاع أو انخفاض ضغط الدم؛ تورد الجلد</li><li>ضيق في التنفس</li><li>عسر الهضم؛ الإمساك</li><li>قصور في الكبد؛ زيادة إنزيمات الكبد (جاما - جلوتاميل ترانسفيراز)؛ اليرقان (اصفرار الجلد أو بياض العينين الناجمين عن مشاكل في الكبد أو الدم)؛ انخفاض صفراء المرارة التي تصل إلى الأمعاء (ركود صفراوي)؛ تضخم الكبد؛ التهاب الكبد</li><li>طفح جلدي مع حكة (الشرى)؛ حكة؛ تورد الجلد (حمامى)</li><li>اختبارات وظائف الكلى غير الطبيعية (زيادة الكرياتينين في الدم؛ زيادة اليوريا في الدم)؛ القصور الكلوي الشديد</li><li>زيادة في أنزيم يسمى نازع هيدروجين&nbsp;اللاكتات</li><li>تخثر الوريد في موضع الحقن؛ التهاب في موضع الحقن؛ ألم في موضع الحقن؛ تجمع السوائل في جسمك</li></ul><p>&nbsp;</p><p><strong>نادرة</strong> (قد تؤثر على ما يصل إلى شخص من 1,000 شخص)</p><ul dir="rtl"><li>فقر الدم بسبب تكسر خلايا الدم الحمراء (فقر الدم الانحلالي)، تكسر خلايا الدم الحمراء (انحلال الدم).</li></ul><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير التكرار من البيانات المتاحة)</p><ul dir="rtl"><li>اضطراب نظام تخثر الدم</li><li>صدمة (تحسسية)</li><li>تلف خلايا الكبد بما في ذلك الموت</li><li>مشاكل في الكلى؛ الفشل الكلوي الحاد</li></ul><p dir="RTL"><strong><em>آثار جانبية إضافية في الأطفال والمراهقين</em></strong></p><p dir="RTL">تم الإبلاغ عن ردود الفعل التالية في كثير من الأحيان في مرضى الأطفال من المرضى البالغين:</p><p dir="RTL"><strong>شائعة</strong> (قد تؤثر على ما يصل إلى شخص من 10 أشخاص)</p><ul dir="rtl"><li>انخفاض عدد الصفائح الدموية (نقص الصفيحات)</li><li>زيادة معدل ضربات القلب (تسارع ضربات القلب)</li><li>ارتفاع أو انخفاض ضغط الدم</li><li>زيادة صبغة صفراء المرارة في الدم (فرط بيليروبين الدم)؛ تضخم الكبد</li><li>الفشل الكلوي الحاد؛ زيادة اليوريا في الدم</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">الزجاجة غير المفتوحة: لا يحفظ عند درجة حرارة أعلى من 30&deg; مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية.</p><p dir="RTL">يجب استخدام المركز المعاد حلّه ومحلول التسريب المخفف على الفور، لأنه لا يحتوي على أي مواد حافظة لمنع التلوث البكتيري. فقط أخصائي الرعاية الصحية المدرب والذي قرأ التوجيهات الكاملة بشكل صحيح يمكنه تحضير هذا الدواء للاستخدام.</p><p dir="RTL">من أجل حماية القنينة/كيس التسريب الذي يحتوي على محلول التسريب المخفف من الضوء، يجب وضعه في كيس معتم محكم الإغلاق.</p><p dir="RTL">الزجاجة للاستخدام الفردي فقط. لذلك، يرجى التخلص من المركز المعاد تشكيله غير المستخدم على الفور.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تستخدم محلول التسريب المخفف إذا كان غائماً أو فيه ترسبات.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي ميكافونجين الصوديوم.</p><p dir="RTL">تحتوي كل زجاجة من ميجمنتو 50 ملغم مسحوق للحل قبل التسريب على 50.86 ملغم ميكافونجين الصوديوم يكافئ 50 ملغم ميكافونجين.</p><p dir="RTL">تحتوي كل زجاجة من ميجمنتو 100 ملغم مسحوق للحل قبل التسريب على 101.73 ملغم ميكافونجين الصوديوم يكافئ 100 ملغم ميكافونجين.</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي لاكتوز أحادي الماء، حمض الستريك اللامائي وهيدروكسيد الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو الشكل الصيدلاني لميجمنتو ووصفه و حجم عبوته</strong></p><p dir="RTL">ميجمنتو 50 ملغم مسحوق للحل قبل التسريب هو مسحوق لونه أبيض خالي من علامات التلوث الظاهرة في زجاجات كهرلية أنبوبية من النوع I حجمها 10 مللتر وعنقها 20 مللمتر، مع سدادات من البروموبيوتيل 20 مللمتر و 20 مللمتر أغطية لونها أزرق من الألومنيوم القابل للفتح للأعلى.</p><p dir="RTL">ميجمنتو 100 ملغم مسحوق للحل قبل التسريب هو مسحوق لونه أبيض خالي من علامات التلوث الظاهرة في زجاجات كهرلية أنبوبية من النوع I حجمها 10 مللتر وعنقها 20 مللمتر، مع سدادات من البروموبيوتيل 20 مللمتر و 20 مللمتر أغطية لونها أحمر من الألومنيوم القابل للفتح للأعلى.</p><p dir="RTL">حجم العبوة: زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 4980170 (11-966) +<br />فاكس:&nbsp; 4980187 (11-966) +<br />البريد الإلكتروني: medical@jpi.com.sa</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">شركة أدوية الحكمة<br />إسترادا دو ريو دا مو، مبنى رقم 8, 8A e 8B<br />فارفانسا<br />سنترا، البرتغال<br />هاتف:&nbsp; 19608410 (2-351) +<br />فاكس: 19615102 (2-351) +</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 05/2019، رقم النسخة: SA1.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Megmento 50 mg Powder for Solution for Infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains 50.86 mg micafungin sodium equivalent to 50 mg micafungin.
Excipient with known effect: sodium.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for infusion
White cake free from visible signs of contamination.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Megmento is indicated for:</p><p><u>Adults, adolescents &ge; 16 years of age and elderly:</u></p><ul><li>Treatment of invasive candidiasis.</li><li>Treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate.</li><li>Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count &lt; 500 cells / &micro;l) for 10 or more days.</li></ul><p><u>Children (including neonates) and adolescents &lt; 16 years of age:</u></p><ul><li>Treatment of invasive candidiasis.</li><li>Prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count &lt; 500 cells / &micro;l) for 10 or more days.</li></ul><p>The decision to use Megmento should take into account a potential risk for the development of liver tumours (see section 4.4). Megmento should therefore only be used if other antifungals are not appropriate.</p><p>Consideration should be given to official/national guidance on the appropriate use of antifungal agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with Megmento should be initiated by a physician experienced in the management of fungal infections.</p><p><u>Posology</u></p><p>Specimens for fungal culture and other relevant laboratory studies (including histopathology) should be obtained prior to therapy to isolate and identify causative organism(s). Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.</p><p>The dose regimen of micafungin depends on the body weight of the patient as given in the following tables:</p><p><em>Use in adults, adolescents &ge; 16 years of age and elderly</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><u>Indication</u></p></td><td colspan="2">&nbsp;</td></tr><tr><td>&nbsp;</td><td><p>Body weight &gt; 40 kg</p></td><td><p>Body weight &le; 40 kg</p></td></tr><tr><td><p>Treatment of invasive candidiasis</p></td><td><p>100 mg/day*</p></td><td><p>2 mg/kg/day*</p></td></tr><tr><td><p>Treatment of oesophageal candidiasis</p></td><td><p>150 mg/day</p></td><td><p>3 mg/kg/day</p></td></tr><tr><td><p>Prophylaxis of&nbsp;<em>Candida</em>&nbsp;infection</p></td><td><p>50 mg/day</p></td><td><p>1 mg/kg/day</p></td></tr></tbody></table><p>*If the patient&#39;s response is inadequate, e.g. persistence of cultures or if clinical condition does not improve, the dose may be increased to 200 mg/day in patients weighing &gt; 40 kg or 4 mg/kg/day in patients &le; 40 kg.</p><p><em>Treatment duration</em></p><p>Invasive candidiasis: The treatment duration of&nbsp;<em>Candida</em>&nbsp;infection should be a minimum of 14 days. The antifungal treatment should continue for at least one week after two sequential negative blood cultures have been obtained and&nbsp;<em>after</em>&nbsp;resolution of clinical signs and symptoms of infection.</p><p>Oesophageal candidiasis: Micafungin should be administered for at least one week after resolution of clinical signs and symptoms.</p><p>Prophylaxis of&nbsp;<em>Candida&nbsp;</em>infections: Micafungin should be administered for at least one week after neutrophil recovery.</p><p><em>Use in children &ge; 4 months of age up to adolescents &lt; 16 years of age</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><u>Indication</u></p></td><td colspan="2">&nbsp;</td></tr><tr><td>&nbsp;</td><td><p>Body weight &gt; 40 kg</p></td><td><p>Body weight &le; 40 kg</p></td></tr><tr><td><p>Treatment of invasive candidiasis</p></td><td><p>100 mg/day*</p></td><td><p>2 mg/kg/day*</p></td></tr><tr><td><p>Prophylaxis of&nbsp;<em>Candida</em>&nbsp;infection</p></td><td><p>50 mg/day</p></td><td><p>1 mg/kg/day</p></td></tr></tbody></table><p>*If the patient&#39;s response is inadequate, e.g. persistence of cultures or if clinical condition does not improve, the dose may be increased to 200 mg/day in patients weighing &gt; 40 kg or 4 mg/kg/day in patients weighing &le; 40 kg.</p><p><em>Use in children (including neonates) &lt; 4 months of age</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><u>Indication</u></p></td><td>&nbsp;</td></tr><tr><td><p>Treatment of invasive candidiasis</p></td><td><p>4 -10 mg/kg/day<em>*</em></p></td></tr><tr><td><p>Prophylaxis of&nbsp;<em>Candida</em>&nbsp;infection</p></td><td><p>2 mg/kg/day</p></td></tr></tbody></table><p>*Micafungin dosed at 4 mg/kg in children less than 4 months approximates drug exposures achieved in adults receiving 100 mg/day for the treatment of invasive candidiasis. If central nervous system (CNS) infection is suspected, a higher dosage (e.g. 10 mg/kg) should be used due to the dose-dependent penetration of micafungin into the CNS (see section 5.2).</p><p><em>Treatment duration</em></p><p>Invasive candidiasis: The treatment duration of&nbsp;<em>Candida</em>&nbsp;infection should be a minimum of 14 days. The antifungal treatment should continue for at least one week after two sequential negative blood cultures have been obtained and&nbsp;<em>after</em>&nbsp;resolution of clinical signs and symptoms of infection.</p><p>Prophylaxis of Candida infections: Micafungin should be administered for at least one week after neutrophil recovery. Experience with Megmento in patients less than 2 years of age is limited.</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary in patients with mild or moderate hepatic impairment (see section 5.2). There are currently insufficient data available for the use of micafungin in patients with severe hepatic impairment and its use is not recommended in these patients (see sections 4.4 and 5.2).</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary in patients with renal impairment (see section 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy in children (including neonates) less than 4 months of age of doses of 4 and 10 mg/kg for the treatment of invasive candidiasis with CNS involvement has not been adequately established. Currently available data are described in section 4.8, 5.1, 5.2.</p><p><u>Method of administration</u></p><p>For intravenous use.</p><p>After reconstitution and dilution, the solution should be administered by intravenous infusion over approximately 1 hour. More rapid infusions may result in more frequent histamine mediated reactions.</p><p>For reconstitution instructions see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to other echinocandins or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatic effects:</u></p><p>The development of foci of altered hepatocytes (FAH) and hepatocellular tumours after a treatment period of 3 months or longer were observed in rats. The assumed threshold for tumour development in rats is approximately in the range of clinical exposure. The clinical relevance of this finding is not known. Liver function should be carefully monitored during micafungin treatment. To minimise the risk of adaptive regeneration and potentially subsequent liver tumour formation, early discontinuation in the presence of significant and persistent elevation of ALT/AST is recommended. Micafungin treatment should be conducted on a careful risk/benefit basis, particularly in patients having severe liver function impairment or chronic liver diseases known to represent preneoplastic conditions, such as advanced liver fibrosis, cirrhosis, viral hepatitis, neonatal liver disease or congenital enzyme defects, or receiving a concomitant therapy including hepatotoxic and/or genotoxic properties.</p><p>Micafungin treatment was associated with significant impairment of liver function (increase of ALT, AST or total bilirubin &gt; 3 times ULN) in both healthy volunteers and patients. In some patients more severe hepatic dysfunction, hepatitis, or hepatic failure including fatal cases have been reported. Paediatric patients &lt; 1 year of age might be more prone to liver injury (see section 4.8).</p><p><u>Anaphylactic reactions</u></p><p>During administration of micafungin, anaphylactic/anaphylactoid reactions, including shock, may occur. If these reactions occur, micafungin infusion should be discontinued and appropriate treatment administered.</p><p><u>Skin reactions</u></p><p>Exfoliative cutaneous reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. If patients develop a rash they should be monitored closely and micafungin discontinued if lesions progress.</p><p><u>Haemolysis</u></p><p>Rare cases of haemolysis, including acute intravascular haemolysis or haemolytic anaemia, have been reported in patients treated with micafungin. Patients who develop clinical or laboratory evidence of haemolysis during micafungin therapy should be monitored closely for evidence of worsening of these conditions and evaluated for the risk/benefit of continuing micafungin therapy.</p><p><u>Renal effects</u></p><p>Micafungin may cause kidney problems, renal failure, and abnormal renal function test. Patients should be closely monitored for worsening of renal function.</p><p><u>Interactions with other medicinal products</u></p><p>Co-administration of micafungin and amphotericin B desoxycholate should only be used when the benefits clearly outweigh the risks, with close monitoring of amphotericin B desoxycholate toxicities (see section 4.5).</p><p>Patients receiving sirolimus, nifedipine or itraconazole in combination with micafungin should be monitored for sirolimus, nifedipine or itraconazole toxicity and the sirolimus, nifedipine or itraconazole dosage should be reduced if necessary (see section 4.5).</p><p><u>Paediatric population</u></p><p>The incidence of some adverse reactions was higher in paediatric patients than in adult patients (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Micafungin has a low potential for interactions with medicines metabolised via CYP3A mediated pathways.</p><p>Drug interaction studies in healthy human subjects were conducted to evaluate the potential for interaction between micafungin and mycophenolate mofetil, ciclosporin, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, rifampicin, itraconazole, voriconazole and amphotericin B. In these studies, no evidence of altered pharmacokinetics of micafungin was observed. No micafungin dose adjustments are necessary when these medicines are administered concomitantly. Exposure (AUC) of itraconazole, sirolimus and nifedipine was slightly increased in the presence of micafungin (22%, 21% and 18% respectively).</p><p>Co-administration of micafungin and amphotericin B desoxycholate was associated with a 30% increase in amphotericin B desoxycholate exposure. Since this may be of clinical significance this co-administration should only be used when the benefits clearly outweigh the risks, with close monitoring of amphotericin B desoxycholate toxicities (see section 4.4).</p><p>Patients receiving sirolimus, nifedipine or itraconazole in combination with micafungin should be monitored for sirolimus, nifedipine or itraconazole toxicity and the sirolimus, nifedipine or itraconazole dosage should be reduced if necessary (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnancy category: C.</p><p>There are no data from the use of micafungin in pregnant women. In animal studies micafungin crossed the placental barrier and reproductive toxicity was seen (see section 5.3). The potential risk for humans is unknown.</p><p>Megmento should not be used during pregnancy unless clearly necessary.</p><p><u>Breast-feeding</u></p><p>It is not known whether micafungin is excreted in human breast milk. Animal studies have shown excretion of micafungin in breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with micafungin should be made taking into account the benefit of breast-feeding to the child and the benefit of micafungin therapy to the mother.</p><p><u>Fertility</u></p><p>Testicular toxicity was observed in animal studies (see section 5.3). Micafungin may have the potential to affect male fertility in humans.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Micafungin has no or negligible influence on the ability to drive or use machines. However, patients should be informed that dizziness has been reported during treatment with micafungin (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Based on clinical trial experience, overall 32.2% of the patients experienced adverse drug reactions. The most frequently reported adverse reactions were nausea (2.8%), blood alkaline phosphatase increased (2.7%), phlebitis (2.5%, primarily in HIV infected patients with peripheral lines), vomiting (2.5%), and aspartate aminotransferase increased (2.3%).</p><p><u>Tabulated list of adverse reactions</u></p><p>In the following table adverse reactions are listed by system organ class and MedDRA preferred term. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong></p></td><td><p><strong>Common</strong></p><p>&ge; 1/100 to &lt; 1/10</p></td><td><p><strong>Uncommon</strong></p><p>&ge; 1/1,000 to &lt; 1/100</p></td><td><p><strong>Rare</strong></p><p>&ge; 1/10,000 to &lt; 1/1,000</p></td><td><p><strong>Not known</strong></p><p>(frequency cannot be estimated from available data)</p></td></tr><tr><td><p>Blood and lymphatic system disorders</p></td><td><p>leukopenia, neutropenia, anaemia</p></td><td><p>pancytopenia, thrombocytopenia, eosinophilia, hypoalbuminaemia</p></td><td><p>haemolytic anaemia, haemolysis (see section 4.4)</p></td><td><p>disseminated intravascular coagulation</p></td></tr><tr><td><p>Immune system disorders</p></td><td>&nbsp;</td><td><p>anaphylactic / anaphylactoid reaction (see section 4.4), hypersensitivity</p></td><td>&nbsp;</td><td><p>anaphylactic and anaphylactoid shock (see section 4.4)</p></td></tr><tr><td><p>Endocrine disorders</p></td><td>&nbsp;</td><td><p>hyperhidrosis</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Metabolism and nutritional disorders</p></td><td><p>hypokalaemia, hypomagnesaemia, hypocalcaemia</p></td><td><p>hyponatraemia, hyperkalaemia, hypophosphataemia, anorexia</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Psychiatric disorders</p></td><td>&nbsp;</td><td><p>insomnia, anxiety, confusion</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Nervous system disorders</p></td><td><p>headache</p></td><td><p>somnolence, tremor, dizziness, dysgeusia</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Cardiac disorders</p></td><td>&nbsp;</td><td><p>tachycardia, palpitations, bradycardia</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Vascular disorders</p></td><td><p>phlebitis</p></td><td><p>hypotension, hypertension, flushing</p></td><td>&nbsp;</td><td><p>shock</p></td></tr><tr><td><p>Respiratory, thoracic and mediastinal disorders</p></td><td>&nbsp;</td><td><p>dyspnoea</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>nausea, vomiting, diarrhoea, abdominal pain</p></td><td><p>dyspepsia, constipation</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>blood alkaline phosphatase increased, aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased (including hyperbilirubinaemia), liver function test abnormal</p></td><td><p>hepatic failure (see section 4.4), gamma-glutamyltransferase increased, jaundice, cholestasis, hepatomegaly, hepatitis</p></td><td>&nbsp;</td><td><p>hepatocellular damage including fatal cases (see section 4.4)</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>rash</p></td><td><p>urticaria, pruritus, erythema</p></td><td>&nbsp;</td><td><p>toxic skin eruption, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (see section 4.4)</p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td>&nbsp;</td><td><p>blood creatinine increased, blood urea increased, renal failure aggravated</p></td><td>&nbsp;</td><td><p>renal impairment (see section 4.4), acute renal failure</p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>pyrexia, rigors</p></td><td><p>injection site thrombosis, infusion site inflammation, injection site pain, peripheral oedema</p></td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Investigations</p></td><td>&nbsp;</td><td><p>blood lactate dehydrogenase increased</p></td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><u>Description of selected adverse reactions</u></p><p><em>Possible allergic-like symptoms</em></p><p>Symptoms such as rash and rigors have been reported in clinical studies. The majority were of mild to moderate intensity and not treatment limiting. Serious reactions (e.g. anaphylactoid reaction 0.2%, 6/3028) were uncommonly reported during therapy with micafungin and only in patients with serious underlying conditions (e.g. advanced AIDS, malignancies) requiring multiple co-medications.</p><p><em>Hepatic adverse reactions</em></p><p>The overall incidence of hepatic adverse reactions in the patients treated with micafungin in clinical studies was 8.6% (260/3028). The majority of hepatic adverse reactions were mild and moderate. Most frequent reactions were increase in AP (2.7%), AST (2.3%), ALT (2.0%), blood bilirubin (1.6%) and liver function test abnormal (1.5%). Few patients (1.1%; 0.4% serious) discontinued treatment due to a hepatic event. Cases of serious hepatic dysfunction occurred uncommonly (see section 4.4).</p><p><em>Injection-site reactions</em></p><p>None of the injection-site adverse reactions were treatment limiting.</p><p><u>Paediatric population</u></p><p>The incidence of some adverse reactions (listed in the table below) was higher in paediatric patients than in adult patients. Additionally, paediatric patients &lt; 1 year of age experienced about two times more often an increase in ALT, AST and AP than older paediatric patients (see section 4.4). The most likely reason for these differences were different underlying conditions compared with adults or older paediatric patients observed in clinical studies. At the time of entering the study, the proportion of paediatric patients with neutropenia was several-fold higher than in adult patients (40.2% and 7.3% of children and adults, respectively), as well as allogeneic HSCT (29.4% and 13.4%, respectively) and haematological malignancy (29.1% and 8.7%, respectively).</p><p><em>Blood and lymphatic system disorders</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td><p>common</p></td><td><p>thrombocytopenia</p></td></tr><tr><td><p><em>Cardiac disorders</em></p></td><td>&nbsp;</td></tr><tr><td><p>common</p></td><td><p>tachycardia</p></td></tr><tr><td><p><em>Vascular disorders</em></p></td><td>&nbsp;</td></tr><tr><td><p>common</p></td><td><p>hypertension, hypotension</p></td></tr><tr><td><p><em>Hepatobiliary disorders</em></p></td><td>&nbsp;</td></tr><tr><td><p>common</p></td><td><p>hyperbilirubinaemia, hepatomegaly</p></td></tr><tr><td><p><em>Renal and urinary disorders</em></p></td><td>&nbsp;</td></tr><tr><td><p>common</p></td><td><p>acute renal failure, blood urea increased</p></td></tr></tbody></table><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>Fax: + (966-11) 2057662</p><p>Toll free: 800-249-0000</p><p>Phone No.: + (966-11) 2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>e-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><ul><li>Other GCC States:</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repeated daily doses up to 8 mg/kg (maximum total dose 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. In one spontaneous case, it was reported a dosage of 16 mg/kg/day was administered in a newborn patient. No adverse reactions associated with this high dose were noted.</p><p>There is no experience with overdoses of micafungin. In case of overdose, general supportive measures and symptomatic treatment should be administered. Micafungin is highly protein-bound and not dialysable.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antimycotics for systemic use, other antimycotics for systemic use, ATC code: J02AX05</p><p><u>Mode of action</u></p><p>Micafungin non-competitively inhibits the synthesis of 1,3-&beta;-D-glucan, an essential component of the fungal cell wall. 1,3-&beta;-D-glucan is not present in mammalian cells.</p><p>Micafungin exhibits fungicidal activity against most&nbsp;<em>Candida</em>&nbsp;species and prominently inhibits actively growing hyphae of&nbsp;<em>Aspergillus</em>&nbsp;species.</p><p><strong>&nbsp;</strong><u>PK/PD relationship</u></p><p>In animals models of candidiasis, a correlation was observed between exposure of micafungin divided by MIC (AUC/MIC) and efficacy defined as the ratio required to prevent progressive fungal growth. A ratio of ~2400 and ~1300 was required for&nbsp;<em>C. albicans&nbsp;</em>and<em>&nbsp;C. glabrata</em>, respectively, in these models. At the recommended therapeutic dosage of micafungin, these ratios are achievable for the wild-type distribution of&nbsp;<em>Candida spp</em>.</p><p><u>Mechanism(s) of resistance</u></p><p>As for all antimicrobial agents, cases of reduced susceptibility and resistance have been reported and cross-resistance with other echinocandins cannot be excluded. Reduced susceptibility to echinocandins has been associated with mutations in the Fks1 and Fks2 genes coding for a major subunit of glucan synthase.</p><p><u>Breakpoints</u></p><p>EUCAST breakpoints</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><em>Candida species</em></p></td><td colspan="2"><p>MIC breakpoint (mg/L)</p></td></tr><tr><td><p>&le;S (Susceptible)</p></td><td><p>&gt;R (Resistant)</p></td></tr><tr><td><p><em>Candida albicans</em></p></td><td><p>0.016</p></td><td><p>0.016</p></td></tr><tr><td><p><em>Candida glabrata</em></p></td><td><p>0.03</p></td><td><p>0.03</p></td></tr><tr><td><p><em>Candida parapsilosis</em></p></td><td><p>0.002</p></td><td><p>2</p></td></tr><tr><td><p><em>Candida tropicalis&nbsp;<strong><sup>1</sup></strong></em></p></td><td colspan="2"><p>Insufficient evidence</p></td></tr><tr><td><p><em>Candida krusei<strong><sup>1</sup></strong></em></p></td><td colspan="2"><p>Insufficient evidence</p></td></tr><tr><td><p><em>Candida guilliermondii<strong><sup>1</sup></strong></em></p></td><td colspan="2"><p>Insufficient evidence</p></td></tr><tr><td><p>Other<em>&nbsp;Candida spp.</em></p></td><td colspan="2"><p>Insufficient evidence</p></td></tr><tr><td colspan="3"><p><strong><sup>1</sup></strong>&nbsp;MICs for&nbsp;<em>C. tropicalis</em>&nbsp;are 1-2 two-fold dilution steps higher than for&nbsp;<em>C albicans</em>&nbsp;and&nbsp;<em>C. glabrata</em>. In the clinical study, successful outcome was numerically slightly lower for&nbsp;<em>C. tropicalis</em>&nbsp;than for&nbsp;<em>C. albicans</em>&nbsp;at both dosages (100 and 150 mg daily). However, the difference was not significant and whether it translates into a relevant clinical difference is unknown. MICs for&nbsp;<em>C. krusei</em>&nbsp;are approximately 3 two-fold dilution steps higher than those for&nbsp;<em>C. albicans</em>&nbsp;and, similarly, those for&nbsp;<em>C. guilliermondii</em>&nbsp;are approximately 8 two-fold dilutions higher. In addition, only a small number of cases involved these species in the clinical trials. This means there is insufficient evidence to indicate whether the wild-type population of these pathogens can be considered susceptible to micafungin.</p></td></tr></tbody></table><p><u>Information from clinical studies</u></p><p><em>Candidaemia and Invasive Candidiasis:</em>&nbsp;Micafungin (100 mg/day or 2 mg/kg/day) was as effective as and better tolerated than liposomal amphotericin B (3 mg/kg) as first-line treatment of candidaemia and invasive candidiasis in a randomised, double-blind, multinational non-inferiority study. Micafungin and liposomal amphotericin B were received for a median duration of 15 days (range, 4 to 42 days in adults; 12 to 42 days in children).</p><p>Non-inferiority was proven for adult patients, and similar findings were demonstrated for the paediatric subpopulations (including neonates and premature infants). Efficacy findings were consistent, independent of the infective&nbsp;<em>Candida&nbsp;</em>species, primary site of infection and neutropenic status (see Table). Micafungin demonstrated a smaller mean peak decrease in estimated glomerular filtration rate during treatment (p&lt;0.001) and a lower incidence of infusion-related reactions (p=0.001) than liposomal amphotericin B.</p><p><strong>Overall Treatment Success in the Per Protocol Set, Invasive Candidiasis Study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2">&nbsp;</td><td colspan="2"><p><strong>Micafungin</strong></p></td><td colspan="2"><p><strong>Liposomal Amphotericin B</strong></p></td><td><p><strong>% Difference</strong></p><p><strong>[95% CI]</strong></p></td></tr><tr><td><p><strong>N</strong></p></td><td><p><strong>n (%)</strong></p></td><td><p><strong>N</strong></p></td><td><p><strong>n (%)</strong></p></td><td>&nbsp;</td></tr><tr><td colspan="6"><p><strong>Adult Patients</strong></p></td></tr><tr><td><p>Overall Treatment Success</p></td><td><p>202</p></td><td><p>181 (89.6)</p></td><td><p>190</p></td><td><p>170 (89.5)</p></td><td><p>0.1 [-5.9, 6.1]&nbsp;<strong>&dagger;</strong></p></td></tr><tr><td colspan="6"><p>Overall Treatment Success by Neutropenic Status</p></td></tr><tr><td><p>Neutropenia at baseline</p></td><td><p>24</p></td><td><p>18 (75.0)</p></td><td><p>15</p></td><td><p>12 (80.0)</p></td><td rowspan="2"><p>0.7 [-5.3, 6.7] &Dagger;</p></td></tr><tr><td><p>No neutropenia at baseline</p></td><td><p>178</p></td><td><p>163 (91.6)</p></td><td><p>175</p></td><td><p>158 (90.3)</p></td></tr><tr><td colspan="6"><p><strong>Paediatric Patients</strong></p></td></tr><tr><td><p>Overall Treatment Success</p></td><td><p>48</p></td><td><p>35 (72.9)</p></td><td><p>50</p></td><td><p>38 (76.0)</p></td><td rowspan="5"><p>-2.7 [-17.3, 11.9] &sect;</p></td></tr><tr><td><p>&lt; 2 years old</p></td><td><p>26</p></td><td><p>21 (80.8)</p></td><td><p>31</p></td><td><p>24 (77.4)</p></td></tr><tr><td><p>Premature Infants</p></td><td><p>10</p></td><td><p>7 (70.0)</p></td><td><p>9</p></td><td><p>6 (66.7)</p></td></tr><tr><td><p>Neonates (0 days to &lt; 4 weeks)</p></td><td><p>7</p></td><td><p>7 (100)</p></td><td><p>5</p></td><td><p>4 (80)</p></td></tr><tr><td><p>2 to 15 years old</p></td><td><p>22</p></td><td><p>14 (63.6)</p></td><td><p>19</p></td><td><p>14 (73.7)</p></td></tr><tr><td colspan="6"><p><strong>Adults and Children Combined, Overall Treatment Success by&nbsp;<em>Candida</em>&nbsp;Species</strong></p></td></tr><tr><td><p><em>Candida albicans</em></p></td><td><p>102</p></td><td><p>91 (89.2)</p></td><td><p>98</p></td><td><p>89 (90.8)</p></td><td rowspan="4">&nbsp;</td></tr><tr><td><p>Non-<em>albicans</em>&nbsp;species&nbsp;<em>&para;</em>: all</p></td><td><p>151</p></td><td><p>133 (88.1)</p></td><td><p>140</p></td><td><p>123 (87.9)</p></td></tr><tr><td><p><em>C. tropicalis</em></p></td><td><p>59</p></td><td><p>54 (91.5)</p></td><td><p>51</p></td><td><p>49 (96.1)</p></td></tr><tr><td><p><em>C. parapsilosis</em></p></td><td><p>48</p></td><td><p>41 (85.4)</p></td><td><p>44</p></td><td><p>35 (79.5)</p></td></tr><tr><td><p><em>C. glabrata</em></p></td><td><p>23</p></td><td><p>19 (82.6)</p></td><td><p>17</p></td><td><p>14 (82.4)</p></td><td>&nbsp;</td></tr><tr><td><p><em>C. krusei</em></p></td><td><p>9</p></td><td><p>8 (88.9)</p></td><td><p>7</p></td><td><p>6 (85.7)</p></td><td>&nbsp;</td></tr></tbody></table><p>&dagger; Micafungin rate minus the liposomal amphotericin B rate, and 2-sided 95% confidence interval for the difference in overall success rate based on large sample normal approximation.</p><p>&Dagger; Adjusted for neutropenic status; primary endpoint.</p><p>&sect; The paediatric population was not sized to test for non-inferiority.</p><p>&para;&nbsp;Clinical efficacy was also observed (&lt; 5 patients) in the following&nbsp;Candida&nbsp;species:&nbsp;C. guilliermondii,&nbsp;C. famata,&nbsp;C. lusitaniae,&nbsp;C. utilis,&nbsp;C. inconspicua&nbsp;and&nbsp;C. dubliniensis.</p><p><em>Oesophageal Candidiasis:</em>&nbsp;In a randomised, double-blind study of micafungin versus fluconazole in the first-line treatment of oesophageal candidiasis, 518 patients received at least a single dose of study drug. The median treatment duration was 14 days and the median average daily dose was 150 mg for micafungin (N=260) and 200 mg for fluconazole (N=258). An endoscopic grade of 0 (endoscopic cure) at the end of treatment was observed for 87.7% (228/260) and 88.0% (227/258) of patients in the micafungin and fluconazole groups, respectively (95% CI for difference: [-5.9%, 5.3%]). The lower limit of the 95% CI was above the predefined non-inferiority margin of -10%, proving non-inferiority. The nature and incidence of adverse events were similar between treatment groups.</p><p><em>Prophylaxis:</em>&nbsp;Micafungin was more effective than fluconazole in preventing invasive fungal infections in a population of patients at high risk of developing a systemic fungal infection (patients undergoing haematopoietic stem cell transplantation [HSCT] in a randomised, double-blind, multicentre study). Treatment success was defined as the absence of a proven, probable, or suspected systemic fungal infection through the end of therapy and absence of a proven or probable systemic fungal infection through the end of study. Most patients (97%, N=882) had neutropenia at baseline (&lt; 200 neutrophils/&micro;L). Neutropenia persisted for a median of 13 days. There was a fixed daily dose of 50 mg (1.0 mg/kg) for micafungin and 400 mg (8 mg/kg) for fluconazole. The mean period of treatment was 19 days for micafungin and 18 days for fluconazole in the adult population (N=798) and 23 days for both treatment arms in the paediatric population (N=84).</p><p>The rate of treatment success was statistically significantly higher for micafungin than fluconazole (1.6%&nbsp;<em>versus</em>&nbsp;2.4% breakthrough infections). Breakthrough&nbsp;<em>Aspergillus</em>&nbsp;infections were observed in 1&nbsp;<em>versus&nbsp;</em>7 patients, and proven or probable breakthrough&nbsp;<em>Candida&nbsp;</em>infections were observed in 4&nbsp;<em>versus</em>&nbsp;2 patients in the micafungin and fluconazole groups, respectively. Other breakthrough infections were caused by&nbsp;<em>Fusarium&nbsp;</em>(1 and 2 patients, respectively) and&nbsp;<em>Zygomycetes&nbsp;</em>(1 and 0 patients, respectively). The nature and incidence of adverse reactions were similar between treatment groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Pharmacokinetics are linear over the daily dose range of 12.5 mg to 200 mg and 3 mg/kg to 8 mg/kg. There is no evidence of systemic accumulation with repeated administration and steady-state is generally reached within 4 to 5 days.</p><p><u>Distribution</u></p><p>Following intravenous administration concentrations of micafungin show a biexponential decline. The drug is rapidly distributed into tissues.</p><p>In systemic circulation, micafungin is highly bound to plasma protein (&gt; 99%), primarily to albumin. Binding to albumin is independent of micafungin concentration (10-100 &micro;g/ml).</p><p>The volume of distribution at steady state (Vss) was approximately 18-19 litres.</p><p><u>Biotransformation</u></p><p>Unchanged micafungin is the principal circulating compound in systemic circulation. Micafungin has been shown to be metabolised to several compounds; of these M-1 (catechol form), M-2 (methoxy form of M-1) and M-5 (hydroxylation at the side chain) of micafungin have been detected in systemic circulation. Exposure to these metabolites is low and metabolites do not contribute to the overall efficacy of micafungin.</p><p>Even though micafungin is a substrate for CYP3A&nbsp;<em>in vitro</em>, hydroxylation by CYP3A is not a major pathway for micafungin metabolism&nbsp;<em>in vivo</em>.</p><p><u>Elimination and excretion</u></p><p>The mean terminal half-life is approximately 10-17 hours and stays consistent across doses up to 8 mg/kg and after single and repeated administration. Total clearance was 0.15-0.3 ml/min/kg in healthy subjects and adult patients and is independent of dose after single and repeated administration.</p><p>Following a single intravenous dose of&nbsp;<sup>14</sup>C-micafungin (25 mg) to healthy volunteers, 11.6% of the radioactivity was recovered in the urine and 71.0% in the faeces over 28 days. These data indicate that elimination of micafungin is primarily non-renal. In plasma, metabolites M-1 and M-2 were detected only at trace concentrations and metabolite M-5, the more abundant metabolite, accounted for a total of 6.5% relative to parent compound.</p><p><u>Special populations</u></p><p>Paediatric patients: In paediatric patients AUC values were dose proportional over the dose range of 0.5-4 mg/kg. Clearance was influenced by weight, with mean values of weight-adjusted clearance 1.35 times higher in the younger children (4 months to 5 years) and 1.14 times higher in paediatric patients aged 6 to 11 years. Older children (12-16 years) had mean clearance values similar to those determined in adult patients. Mean weight-adjusted clearance in children less than 4 months of age is approximately 2.6-fold greater than older children (12-16 years) and 2.3-fold greater than in adults.</p><p>PK/PD bridging study demonstrated dose-dependent penetration of micafungin into CNS with the minimum AUC of 170 &micro;g*hr/L required to achieve maximum eradication of fungal burden in the CNS tissues. Population PK modeling demonstrated that a dose of 10 mg/kg in children less than 4 month of age would be sufficient to achieve the target exposure for the treatment of CNS&nbsp;<em>Candida</em>&nbsp;infections.</p><p>Elderly: When administered as a single 1-hour infusion of 50 mg the pharmacokinetics of micafungin in the elderly (aged 66-78 years) were similar to those in young (20-24 years) subjects. No dose adjustment is necessary for the elderly.</p><p>Patients with hepatic impairment: In a study performed in patients with moderate hepatic impairment (Child-Pugh score 7-9), (n=8), the pharmacokinetics of micafungin did not significantly differ from those in healthy subjects (n=8). Therefore, no dose adjustment is necessary for patients with mild to moderate hepatic impairment. In a study performed in patients with severe hepatic impairment (Child-Pugh score 10-12) (n=8), lower plasma concentrations of micafungin and higher plasma concentrations of the hydroxide metabolite (M-5) were seen compared to healthy subjects (n=8). These data are insufficient to support a dosing recommendation in patients with severe hepatic impairment.</p><p>Patients with renal impairment: Severe renal impairment (Glomerular Filtration Rate [GFR] &lt; 30 ml/min) did not significantly affect the pharmacokinetics of micafungin. No dose adjustment is necessary for patients with renal impairment.</p><p>Gender/Race: Gender and race (Caucasian, Black and Oriental) did not significantly influence the pharmacokinetic parameters of micafungin. No dose adjustment of micafungin is required based on gender or race.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The development of foci of altered hepatocytes (FAH) and hepatocellular tumours in rats was dependent on both dose and duration of micafungin treatment. FAH recorded after treatment for 13 weeks or longer persisted after a 13-week withdrawal period and developed into hepatocellular tumours following a treatment free period which covered the life span of rats. No standard carcinogenicity studies have been conducted but the development of FAH was assessed in female rats after up to 20 and 18 months after cessation of a 3 and 6 month treatment, respectively. In both studies increased incidences/numbers of hepatocellular tumours were observed after the 18 and 20 month treatment free period in the high dose group of 32 mg/kg/day as well as in a lower dose group (although not statistically significant). The plasma exposure at the assumed threshold for tumour development in rats (i.e. the dose where no FAH and liver tumours were detected) was in the same range as the clinical exposure. The relevance of the hepatocarcinogenic potential of micafungin for the human therapeutic use is not known.</p><p>The toxicology of micafungin following repeated intravenous dosing in rats and/or dogs showed adverse responses in liver, urinary tract, red blood cells, and male reproductive organs. The exposure levels at which these effects did not occur (NOAEL) were in the same range as the clinical exposure or lower. Consequently, the occurrence of these adverse responses may be expected in human clinical use of micafungin.</p><p>In standard safety pharmacology tests, cardiovascular and histamine releasing effects of micafungin were evident and appeared to be time above threshold dependent. Prolongation of infusion time reducing the plasma concentration peak appeared to reduce these effects.</p><p>In repeated dose toxicity studies in rat signs of hepatotoxicity consisted of increased liver enzymes and degenerative changes of hepatocytes which were accompanied by signs of compensatory regeneration. In dog, liver effects consisted of increased weight and centrilobular hypertrophy, no degenerative changes of hepatocytes were observed.</p><p>In rats, vacuolation of the renal pelvic epithelium as well as vacuolation and thickening (hyperplasia) of the bladder epithelium were observed in 26-week repeat dose studies. In a second 26-week study hyperplasia of transitional cells in the urinary bladder occurred with a much lower incidence. These findings showed reversibility over a follow-up period of 18 months. The duration of micafungin dosing in these rat studies (6 months) exceeds the usual duration of micafungin dosing in patients (see section 5.1).</p><p>Micafungin haemolysed rabbit blood&nbsp;<em>in vitro</em>. In rats, signs of haemolytic anaemia were observed after repeated bolus injection of micafungin. In repeat dose studies in dogs, haemolytic anaemia was not observed.</p><p>In reproductive and developmental toxicity studies, reduced birth weight of the pups was noted. One abortion occurred in rabbits at 32 mg/kg/day. Male rats treated intravenously for 9 weeks showed vacuolation of the epididymal ductal epithelial cells, increased epididymis weights and reduced number of sperm cells (by 15%), however, in studies of 13 and 26 weeks duration these changes did not occur. In adult dogs, atrophy of seminiferous tubules with vacuolation of the seminiferous epithelium and decreased sperm in the epididymides were noted after prolonged treatment (39 weeks) but not after 13 weeks of treatment. In juvenile dogs, 39 weeks treatment did not induce lesions in the testis and epididymides in a dose dependent manner at the end of treatment but after a treatment free period of 13 weeks a dose dependent increase in these lesions were noted in the treated recovery groups. No impairment of male or female fertility was observed in the fertility and early embryonic development study in rats.</p><p>Micafungin was not mutagenic or clastogenic when evaluated in a standard battery of&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo&nbsp;</em>tests, including an&nbsp;<em>in vitro</em>study on unscheduled DNA synthesis using rat hepatocytes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;Lactose monohydrate</p><p>-&nbsp;&nbsp;Citric Acid Anhydrous</p><p>-&nbsp;&nbsp;Sodium Hydroxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed or co-infused with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vials
24 months.
Reconstituted concentrate in vial
Chemical and physical in-use stability has been demonstrated for up to 24 hours at 25°C when reconstituted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion.
Diluted infusion solution
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C when protected from light when diluted with sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion.
Megmento contains no preservatives. From a microbiological point of view, the reconstituted and diluted solutions should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless the reconstitution and dilution have taken place in controlled and validated aseptic conditions.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Unopened vials</u></p><p>Do not store above 30&deg;C.</p><p>Store in the original package.</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>10 ml type I tubular amber glass vials with 20 mm neck, 20 mm bromobutyl Lyo stopper and 20 mm blue aluminum flip-off.</p><p>Pack size: 1 vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>Megmento must not be mixed or co-infused with other medicinal products except those mentioned below. Using aseptic techniques at room temperature, Megmento is reconstituted and diluted as follows:</p><p>1.&nbsp; The aluminum flip-off cap must be removed from the vial and the stopper disinfected with alcohol.</p><p>2.&nbsp; Five ml of sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion (taken from a 100 ml bottle/bag) should be aseptically and slowly injected into each vial along the side of the inner wall. Although the concentrate will foam, every effort should be made to minimise the amount of foam generated. A sufficient number of vials of Megmento must be reconstituted to obtain the required dose in mg (see table below).</p><p>3.&nbsp; The vial should be rotated gently. DO NOT SHAKE. The powder will dissolve completely. The concentrate should be used immediately. The vial is for single use only. Therefore, unused reconstituted concentrate must be discarded immediately.</p><p>4.&nbsp; All of the reconstituted concentrate should be withdrawn from each vial and returned into the infusion bottle/bag from which it was originally taken. The diluted infusion solution should be used immediately. Chemical and physical in-use stability has been demonstrated for 24 hours at 25&deg;C when protected from light and diluted as described above.</p><p>5.&nbsp; Dilution: Add the 5 ml of reconstituted Megmento into 100 ml of sodium chloride 9 mg/ml (0.9%) solution for infusion or glucose 50 mg/ml (5%) solution for infusion. Ensure that the final concentration of the solution is between 0.5 mg/mL to 4 mg/ml.</p><p>6.&nbsp; The infusion bottle/bag should be gently inverted to disperse the diluted solution but NOT agitated in order to avoid foaming. The solution must not be used if it is cloudy or has precipitated.</p><p>7.&nbsp; The infusion bottle/bag containing the diluted infusion solution should be inserted into a closable opaque bag for protection from light.</p><p>After reconstitution and dilution, the solution should be administered by intravenous infusion over approximately 1 hour.</p><p>To minimize the risk of infusion reactions, concentrations of greater than 1.5 mg/ml should be administered via central catheter.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. BOX 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 4980170            
Fax: + (966-11) 4980187
e-mail: medical@jpi.com.sa

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 May 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>